Results 51 to 60 of about 492,235 (272)

EFFICACY AND SAFETY OF ALENDRONIC ACID IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

open access: yesПедиатрическая фармакология, 2010
Search for and practical application of new medications to treat of osteoporosis is one of the critical issues in pediatric rheumatology. The article reviews the efficacy and safety of alendronic acid in 64 subjects with juvenile rheumatoid arthritis and
A.O. Lisitsin   +9 more
doaj   +2 more sources

Pulmonary hemosiderosis with juvenile rheumatoid arthritis: a case report

open access: yesThe Turkish Journal of Pediatrics, 2000
Pulmonary hemosiderosis may rarely be associated with juvenile rheumatoid arthritis or can develop during the course of the disease. We present a three-year-old boy with severe iron deficiency anemia (without any pulmonary symptoms) and arthralgia
R Topaloğlu   +4 more
doaj  

Biologic therapy of rheumatoid arthritis [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2009
Rheumatoid arthritis (RA) and juvenile idiopathic/rheumatoid arthritis (JIA) are chronic, inflammatory, systemic, auto-immune diseases characterized by chronic arthritis leading to progressive joint erosions.
Damjanov Nemanja, Vojinović Jelena
doaj   +1 more source

Ten‐Year Post‐traumatic Osteoarthritis Incidence Is Low After Pediatric Isolated Meniscal Surgery but Lower After Meniscal Repair Than Meniscectomy

open access: yesArthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To examine the 5‐ and 10‐year incidence of post‐traumatic osteoarthritis (PTOA) after isolated, primary meniscal surgery differentiating between meniscal repair and meniscectomy, in pediatric patients. Methods Pediatric patients (≤16 years) undergoing primary meniscectomy or meniscal repair (2010‐2023) with ≥5‐year follow‐up were identified in ...
Annika N. Hiredesai   +6 more
wiley   +1 more source

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

open access: yes
Arthritis Care &Research, EarlyView.
Catherine Deffendall   +6 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Cerebral Vasculitis in Juvenile Rheumatoid Arthritis

open access: yesPediatric Neurology Briefs, 1998
A 16-year-old girl who developed a stroke after a 5-year history of polyarticular juvenile rheumatoid arthritis is reported from Tripler Army Medical Center, Honolulu, Hawaii.
J Gordon Millichap
doaj   +1 more source

Treating Rheumatoid Arthritis yesterday and today [PDF]

open access: yes, 2004
Rheumatoid arthritis is a chronic, systemic inflammatory disorder that mainly affects joints. It is the most common form of inflammatory joint disease, and the second commonest joint disease, osteoarthritis being the commonest.
Mallia, Carmel
core  

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz   +13 more
wiley   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner   +52 more
wiley   +1 more source

Home - About - Disclaimer - Privacy